3.660
+0.130
+(3.68%)
At close: January 28 at 12:08:04 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
72,207.000
89,502.000
40,659.000
4,308.000
14,107.000
Cost of Revenue
3,196.000
2,034.000
130.000
137.000
449.000
Gross Profit
69,011.000
87,468.000
40,529.000
4,171.000
13,658.000
Operating Expense
50,568.000
64,801.000
161,856.000
144,350.000
99,098.000
Operating Income
18,443.000
22,667.000
-121,327.000
-140,179.000
-85,440.000
Net Non Operating Interest Income Expense
2,540.000
1,752.000
879.000
2,093.000
546.000
Pretax Income
21,503.000
22,682.000
-137,020.000
-137,829.000
-296,638.000
Tax Provision
257.000
-81.000
248.000
49.000
-99.000
Net Income Common Stockholders
21,299.000
22,797.000
-137,222.000
-137,777.000
-296,397.000
Diluted NI Available to Com Stockholders
21,299.000
22,797.000
-137,222.000
-137,777.000
-296,397.000
Basic EPS
0.03
0.03
-0.19
-0.19
-1.69
Diluted EPS
0.03
0.03
-0.19
-0.19
-1.69
Basic Average Shares
735,136.203
733,944.377
729,435.207
732,377.357
175,804.418
Diluted Average Shares
742,109.302
742,530.010
729,435.207
732,377.357
175,804.418
Total Expenses
53,764.000
66,835.000
161,986.000
144,487.000
99,547.000
Net Income from Continuing & Discontinued Operation
21,299.000
22,797.000
-137,222.000
-137,777.000
-296,397.000
Normalized Income
22,298.905
23,556.000
-128,598.500
-137,915.750
-296,397.000
Interest Income
--
5,624.000
2,866.000
2,269.000
826.000
Interest Expense
3,084.000
3,872.000
1,987.000
176.000
99.000
Net Interest Income
2,540.000
1,752.000
879.000
2,093.000
546.000
EBIT
24,587.000
26,554.000
-135,033.000
-137,653.000
-296,539.000
EBITDA
28,534.000
31,185.000
-126,998.000
-130,844.000
-290,910.000
Reconciled Cost of Revenue
3,196.000
2,034.000
130.000
137.000
449.000
Reconciled Depreciation
3,947.000
4,631.000
8,035.000
6,809.000
5,629.000
Net Income from Continuing Operation Net Minority Interest
21,299.000
22,797.000
-137,222.000
-137,777.000
-296,397.000
Total Unusual Items Excluding Goodwill
-1,012.000
-1,012.000
-11,498.000
185.000
--
Total Unusual Items
-1,012.000
-1,012.000
-11,498.000
185.000
--
Normalized EBITDA
29,546.000
32,197.000
-115,500.000
-131,029.000
-290,910.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-12.095
-253.000
-2,874.500
46.250
--
12/31/2020 - 12/10/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2162.HK Keymed Biosciences Inc.
29.500
-2.48%
9688.HK Zai Lab Limited
20.900
+1.95%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
159.300
-0.62%
2126.HK JW (Cayman) Therapeutics Co. Ltd
1.390
-0.71%
2511.HK HighTide Therapeutics, Inc.
1.140
-2.56%
2157.HK Lepu Biopharma Co., Ltd.
2.730
-4.88%
3759.HK Pharmaron Beijing Co., Ltd.
14.100
-1.40%
1952.HK Everest Medicines Limited
40.300
-0.86%
1530.HK 3SBIO
6.010
-3.22%
0775.HK CKLIFE SCIENCES
0.520
+5.05%